Common side effects are nausea, diarrhea, vomiting, and constipation, dose dependent and most common during titration. Less common but notable: gallbladder disease, rare pancreatitis, injection site reactions, and aspiration risk under anesthesia. Carries the same boxed warning as semaglutide for thyroid C cell tumor risk observed in rodent studies, with the same contraindication for personal/family history of medullary thyroid carcinoma or MEN 2. Not for use in pregnancy.

What is the dose of Tirzepatide?

No established consumer dosing protocol; see full guide article for regulatory and safety context.

Compound Profile

Tirzepatide

Dual GIP/GLP-1 receptor agonist (prescription drug)

Tirzepatide is a dual GIP/GLP 1 receptor agonist, FDA approved as Mounjaro and Zepbound, showing the largest average weight loss effect of any approved obesity drug to date (up to ~22.

Last reviewed: June 30, 2026

A Strong

Monograph visual

Tirzepatide

Generated profile category visual

Where to go next — guides & comparisons

If you want help sleeping → Sleep guides
If you want to browse more compounds → All compounds

Prescription-only drug: no consumer sourcing

Tirzepatide is an FDA-approved prescription drug (Mounjaro, Zepbound), not a controlled substance, and is not sold as a research peptide. As with semaglutide, the FDA has determined tirzepatide is no longer in shortage, which curtails bulk compounding — compounded access now generally requires individualized, physician-documented clinical necessity.

Legitimate access is prescription-only through a licensed pharmacy.
Carries the same boxed warning as semaglutide for thyroid C-cell tumor risk; same contraindications apply.
This profile is not a self-treatment guide or a substitute for a prescribing clinician.

Regulatory status

2026 federal and state regulatory context

Last checked 2026 06 30

FDA approved and commercially available by prescription. As with semaglutide, the FDA has determined tirzepatide is no longer in shortage, curtailing 503B bulk compounding; compounded access now generally requires individualized physician documented clinical necessity. Not sold as a research peptide.

Regulatory changelog

2026: FDA shortage determination resolved for tirzepatide, winding down the compounded supply era; 503B bulk compounding no longer generally available absent individualized clinical justification.

Quick Stats

Evidence level

Strong evidence

Typical onset

Varies by prep

Safety rating

Use extra caution: Use caution

Best for

Dual GIP And GLP 1 Receptor Agonism, Glucose Dependent Insulin Secretion, Central Appetite Regulation

Avoid / review if

Pregnancy/Breastfeeding, Severe Gastrointestinal Disease Or Gastroparesis, May Cause Additive Hypoglycemia With Insulin Or Sulfonylureas

Safety & Cautions

Review before use if any apply: Pregnancy/Breastfeeding, Severe Gastrointestinal Disease Or Gastroparesis, May Cause Additive Hypoglycemia With Insulin Or Sulfonylureas.

Evidence-based safety

Caution when combined

These pairings share a flagged risk mechanism. They are additive-effect cautions derived from contraindication data, not confirmed clinical interactions. Consult a clinician before combining.

Moderate Caution

110 flagged pairings

Blood-sugar lowering

Browse the grouped cautions below. The list scrolls inside this card when long.

Blood-sugar lowering

Evidence Summary

A Strong

Evidence lens

Most useful for practical interpretation when safety context also fits.

StrongStrong evidence

Human clinical evidence: Present in source signals

Mechanistic / preclinical: Mechanism mapped — Dual GIP And GLP 1 Receptor Agonism · Glucose Dependent Insulin Secretion · Central Appetite Regulation

Research maturity: More interpretable — main contexts: Dual GIP And GLP 1 Receptor Agonism · Glucose Dependent Insulin Secretion · Central Appetite Regulation

Safety boundary: Safety note available — Review before use if any apply: Pregnancy/Breastfeeding, Severe Gastrointestinal Disease Or Gastroparesis, May Cause Additive Hypoglycemia With Insulin Or Sulfonylureas.

Evidence Strength

Confidence estimate based on the design quality and consistency of published clinical trials.

Strong evidence

Tirzepatide has a strong evidence evidence rating.

General wellnessGeneral wellness

Effects

How evidence grades work

Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.

Strong

Multiple RCTs, consistent direction, adequate effect size

Moderate

Some RCTs or consistent observational data in humans

Preliminary / Mixed

Animal or in-vitro only, or conflicting human data

Traditional / Theoretical

Traditional use only; no controlled human trials

How Tirzepatide Works

Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.

Mechanism Pathway — How Tirzepatide Works

CompoundTarget / ReceptorMechanismEffect / Outcome

Mechanisms & Biological Pathways▼

Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.

Dual GIP And GLP 1 Receptor AgonismGlucose Dependent Insulin SecretionCentral Appetite RegulationIncretin Signaling

Compare & Sourcing

Compare side-by-side tradeoffs or verify active marker guidelines.

Free safety checklist

Get the Tirzepatide evidence notes

Occasional research updates, safety context, and product-quality checks for supplement decisions.

We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.

⚠️ Sourcing Options Disabled for Safety

Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.

Evaluate the safety checks, contraindications, and potential medication interactions below under clinician supervision before use.

Safety first · Harm reduction

This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.

Learn how we evaluate confidence, safety, and intensity on the methodology page.

Editorial Review

Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.

Editorial Standards →

← Back to compounds library Safety checker →

Compound profile context

How to interpret Tirzepatide

Tirzepatide dosage by use case, onset and duration, safety limits, and interactions for dual gip and glp 1 receptor agonism, graded against research. Strong… Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.

When reviewing Tirzepatide, separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.

For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.